This page has been fact checked by an experienced mesothelioma Patient Advocate. Sources of information are listed at the bottom of the article.
We make every attempt to keep our information accurate and up-to-date.
Please Contact Us with any questions or comments.
Dr. Robert E. Merritt is a general thoracic surgeon and professor and director of the Division of Thoracic Surgery at Ohio State University. Also serving as director of inpatient services at The James Cancer Hospital, Dr. Merritt has special expertise in minimally invasive surgery in the treatment of lung cancer and thoracic malignancies, including malignant pleural mesothelioma. His clinical interests include primary lung carcinoma, esophageal carcinoma, thymic malignancies, primary tumors of the chest wall, tracheal tumors, and secondary lung carcinoma.
Dr. Merritt’s areas of expertise include thoracotomy, pneumonectomy, bronchoscopy, and video-assisted thoracic surgery. When removing lung tumors and tumors of the mediastinum, Dr. Merritt utilizes robotic-assisted thoracic surgery procedures that are much less invasive. Robotic surgery promotes rapid healing with fewer adverse side effects, fewer infections, and shorter hospital stays.
Education and Career
Dr. Merritt attended medical school at the Weill Medical College of Cornell University. He completed his internship and residency in General Surgery at New York-Presbyterian Hospital and followed that training with a fellowship in Thoracic Surgery and another in Thoracic and Cardiac Surgery at Massachusetts General Hospital in Boston, Massachusetts.
Dr. Merritt has been named to the Castle Connolly list of Regional Top Doctors and rated in the top ten percent of physicians in the nation for patient satisfaction. He has published numerous studies in professional, peer-reviewed journals, including Nature Medicine, The Annals of Thoracic Surgery, Thoracic Surgery Clinics, The Journal of Thoracic and Cardiovascular Surgery, Journal for Immunotherapy of Cancer, and Rapid Communications in Mass Spectrometry.
Dr. Merritt’s research interests include the study of tumor immunology. He has investigated the role of Cisplatin-mediated upregulation of CD40 ligands in lung cancer cell lines. He has also performed outcomes research to improve the results of surgical procedures for thoracic malignancies, including malignant pleural mesothelioma.Get Your FREE Mesothelioma Packet
Written by Terri Oppenheimer
Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.
Page Edited by Patient Advocate Dave Foster
Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.